Group 1 - The core opinion of the article is that the legal opinion regarding the convening and holding of the shareholders' meeting of Runben Biotechnology Co., Ltd. is valid and complies with relevant laws and regulations [1][9] - The shareholders' meeting was convened by the company's second board of directors based on the resolution of the ninth meeting held on August 18, 2025, and was presided over by the chairman Zhao Guiqin [2][3] - The meeting was held on September 3, 2025, at the company's conference room in Guangzhou, with provisions for both on-site and online voting [2][4] Group 2 - A total of 396 participants, including shareholders and their proxies, attended the meeting, representing shares that were verified to be held by eligible shareholders as of the registration date [3][5] - The network voting system was made available for all shareholders, allowing them to choose between on-site and online voting, with the first vote counted in case of duplicates [4][5] - The voting results from both on-site and network votes were combined, and the meeting's resolutions were passed in accordance with the company's articles of association [9] Group 3 - The legal opinion confirms that the procedures for convening and holding the shareholders' meeting, the qualifications of attendees, and the voting procedures are all in compliance with legal requirements and the company's articles of association [9] - The resolutions passed during the meeting were deemed legally valid and effective, with specific attention given to the voting results of minority investors [9]

广东广信君达律师事务所 关于润本生物技术股份有限公司 本律师同意将本法律意见书作为公司本次股东大会的必备文件按有关规定予以公告，并依 法对本律师出具的法律意见承担相应的法律责任。非经本律师书面同意，本法律意见书不得用 于其他任何目的或用途。 1. 公司章程； 2. 第二届董事会第九次会议决议公告； 3. 公司于 2025 年 8 月 19 日在《证券时报》、《中国证券报》、《上海证券报》、巨潮 资讯网（http://www.cninfo.com.cn）刊登的《第二届董事会第九次会议决议公告》、《第二 届监事会第六次会议决议公告》和《关于召开 2025 年第二次临时股东大会的通知》； 4. 公司 2025 年第二次临时股东大会股东到会登记记录及凭证资料； 5. 公司 2025 年第二次临时股东大会会议文件。 本律师仅根据本法律意见书出具日以前发生的事实，及对该事实的了解和对法律法规的理 解，就本次股东大会所涉及的相关法律问题发表法律意见。 2025 年第二次临时股东大会的法律意见书 致：润本生物技术股份有限公司 广东广信君达律师事务所（以下简称"本所"）接受润本生物技术股份有限公司（以下简 称"公司"）的委托， ...

(一)股东大会召开的时间：2025 年 9 月 3 日 (二)股东大会召开的地点：广东省广州市天河区珠江新城华夏路 28 号富力盈信 大厦 40 楼润本生物技术股份有限公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 证券代码：603193 证券简称：润本股份 公告编号：2025-037 润本生物技术股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)非累积投票议案 1、 议案名称：《关于<2025 年半年度利润分配方案>的议案》 审议结果：通过 表决情况： | 1、出席会议的股东和代理人人数 | 396 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 316,735,162 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 78.2848 | (四)表决方式是否符合《公司法》及《公司章 ...

Market Overview - The personal care products sector experienced a decline of 1.87% on September 1, with Haoyue Care leading the drop [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Stock Performance - Notable stock performances include: - Yiyi Co., Ltd. (001206) closed at 25.98, up 2.81% with a trading volume of 91,800 shares and a turnover of 238 million yuan [1] - Haoyue Care (605009) closed at 36.35, down 10.00% with a trading volume of 111,800 shares and a turnover of 408 million yuan [2] - Zhongshun Jierou (002511) closed at 8.64, down 1.48% with a trading volume of 186,900 shares and a turnover of 162 million yuan [2] Capital Flow - The personal care products sector saw a net outflow of 147 million yuan from institutional investors, while retail investors experienced a net inflow of 98.24 million yuan [2] - The capital flow for individual stocks shows: - Ziya Co., Ltd. (003006) had a net inflow of 6.03 million yuan from institutional investors [3] - Haoyue Care (605009) had a significant net outflow of 622.31 million yuan from institutional investors [3]

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The company achieved a revenue of 895 million yuan in the first half of 2025, representing a year-on-year increase of 20.31%, with a net profit attributable to shareholders of 188 million yuan, up 4.16% year-on-year [1][4] - The strong performance in the infant and child care segment is driving growth, with significant contributions from the egg yolk oil special care series and children's sunscreen products [1] - The company is strategically expanding its product matrix to include youth-oriented products, which is expected to enhance user lifetime value and open a second growth curve [3] Summary by Sections Financial Performance - In Q2 2025, the company reported a revenue of 655 million yuan, a year-on-year increase of 13.46%, while the net profit was 143 million yuan, down 0.85% year-on-year [1][4] - The infant care revenue reached 405 million yuan, up 38.73% year-on-year, while the mosquito repellent product growth slowed to 13.43%, totaling 375 million yuan [1][2] - The overall gross margin for H1 2025 was 58.01%, a slight decrease of 0.63 percentage points year-on-year, with a net profit margin of 20.95%, down 3.25 percentage points year-on-year [2] Product and Market Strategy - The company is launching over 40 new products, including a youth acne treatment series and children's sunscreen gel, which are expected to drive revenue growth in the second half of the year [3] - The company is deepening its channel layout, with significant online and offline sales growth, including new partnerships with major retailers [1][2] Future Projections - The company forecasts revenue growth rates of 20.7% for 2023, 27.6% for 2024, and 23.6% for 2025, with net profit growth rates of 41.2%, 32.8%, and 10.2% respectively [3][8] - Expected EPS for 2025 is projected at 0.82 yuan, with a P/E ratio of 37.0 [3][8]

润本生物技术股份有限公司 2025 年第二次临时股东大会会议资料 润本生物技术股份有限公司 2025 年第二次临时股东大会 会议资料 2025 年 8 月 28 日 1 润本生物技术股份有限公司 2025 年第二次临时股东大会会议资料 目 录 | 2025 年第二次临时股东大会须知……………………………………………….…3 | | --- | | 2025 年第二次临时股东大会议程……………………………………………….…5 | | 议案一：关于<2025 年半年度利润分配方案>的议案…………….………….… 7 | | 议案二：《关于取消监事会暨修订<公司章程>的议案》……….………….… 8 | | 议案三：《关于修订<股东大会议事规则>的议案》……….………….……… 9 | | 议案四：《关于修订<董事会议事规则>的议案》……….………….….… 10 | | 议案五：《关于修订<独立董事工作制度>的议案》……….………….… 11 | | 议案六：《关于修订<对外担保管理制度>的议案》……….………….… 12 | | 议案七：《关于修订<对外投资管理制度>的议案》……….………….… 13 | | ...

Core Viewpoint - The company is holding its second extraordinary general meeting of shareholders in 2025 to discuss various proposals aimed at improving corporate governance and financial distribution to shareholders [1][4]. Proposal Summaries Proposal 1: Profit Distribution Plan - The company proposes a cash dividend of 2.00 RMB per 10 shares (including tax) to all shareholders, based on the total share capital as of the dividend record date. This distribution represents a certain percentage of the company's net profit attributable to shareholders for the first half of 2025 [5]. Proposal 2: Cancellation of Supervisory Board - The company plans to cancel the supervisory board and amend its articles of association to enhance governance structure, in compliance with relevant laws and regulations. The board seeks authorization to handle necessary registration and amendments [6]. Proposal 3: Revision of Shareholders' Meeting Rules - The company proposes to revise the rules governing shareholders' meetings to improve operational standards and governance structure, aligning with current legal requirements [7]. Proposal 4: Revision of Board Meeting Rules - The company intends to amend the rules for board meetings to enhance governance and operational efficiency, following legal and regulatory updates [7]. Proposal 5: Revision of Independent Director Work System - The company aims to revise the independent director work system to improve governance and operational standards, in line with legal requirements [7]. Proposal 6: Revision of External Guarantee Management System - The company proposes to amend the external guarantee management system to enhance governance and compliance with legal standards [9]. Proposal 7: Revision of External Investment Management System - The company seeks to revise the external investment management system to improve governance and align with legal regulations [12]. Proposal 8: Revision of Related Party Transaction Management System - The company plans to amend the related party transaction management system to enhance governance and comply with legal standards [12]. Proposal 9: Revision of Accountant Firm Selection System - The company proposes to revise the accountant firm selection system to improve governance and align with legal requirements [13]. Proposal 10: Revision of Controlling Shareholder and Actual Controller Behavior Norms - The company intends to amend the norms governing the behavior of controlling shareholders and actual controllers to enhance governance [13]. Proposal 11: Revision of Cumulative Voting Implementation Rules - The company seeks to revise the implementation rules for cumulative voting to improve governance and operational standards [14]. Proposal 12: Revision of Fundraising Management System - The company proposes to amend the fundraising management system to enhance governance and comply with legal standards [15].

Core Points - The stock price of Runben Co., Ltd. (603193) closed at 30.59 yuan on August 25, 2025, down 1.77% with a turnover rate of 7.73% and a trading volume of 79,900 lots, amounting to 245 million yuan [1] - The company experienced a net outflow of main funds amounting to 58.92 million yuan, accounting for 24.08% of the total transaction amount, with significant outflows from large orders [1] - Runben's latest financial results show total operating revenue of 895 million yuan, a year-on-year increase of 20.31%, and a net profit attributable to shareholders of 188 million yuan, up 4.16% year-on-year [1] Financial Metrics - The company's non-deductible net profit reached 177 million yuan, reflecting a year-on-year growth of 0.86% [1] - Current ratio stands at 10.497, quick ratio at 9.660, and debt-to-asset ratio at 6.98% [1] Company Overview - Runben Biotechnology Co., Ltd. was established in 2013 and is located in Guangzhou, primarily engaged in the manufacturing of chemical raw materials and products [2] - The company has a registered capital of 4,045.93314 million yuan and the same amount in paid-in capital [1] - The legal representative of the company is Zhao Guiqin [1] Investment and Intellectual Property - Runben has made investments in 8 enterprises and participated in 13 bidding projects [2] - The company holds 106 trademark registrations and 109 patents, along with 64 administrative licenses [2]

Group 1 - From August 18 to August 24, brokers issued a total of 463 target prices for listed companies, with the highest target price increases for Hengmingda at 63.83%, Jiangsu Shentong at 62.24%, and Dongfang Caifu at 60.29%, belonging to the consumer electronics, general equipment, and securities industries respectively [1] - A total of 559 listed companies received broker recommendations during the same period, with Beixin Building Materials receiving 22 recommendations, Yanghe Co. receiving 21, and Runben Co. receiving 20 [1] - During this period, brokers upgraded ratings for 9 companies, including Dongbei Securities upgrading Changhai Co. from "Hold" to "Buy", and Pacific Securities upgrading Chuanjinno from "Hold" to "Buy" [1] Group 2 - Brokers downgraded ratings for 11 companies, including Minsheng Securities downgrading Taoli Bread from "Recommended" to "Cautious Recommendation", and Zhongyin International Securities downgrading Southern Airlines from "Hold" to "Increase" [1] - From August 18 to August 24, brokers provided 97 instances of initial coverage, with Southern Airlines receiving an "Increase" rating from Zhongyin International Securities, and Cuihua Jewelry receiving a "Buy" rating from Tianfeng Securities [2] - Other companies receiving initial coverage include Feiyada with a "Buy" rating from Dongbei Securities, Lihua Co. with an "Increase" rating from Huaxi Securities, and Sanhuan Group with a "Buy" rating from Huayuan Securities [2]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The retail industry is experiencing a recovery, with high growth in premium and fashionable segments, particularly in gold jewelry and beauty care [23][27] - The report emphasizes the importance of emotional consumption themes driving growth in high-quality companies within the sector [30] Summary by Sections Retail Market Review - The retail industry index rose by 4.21% during the week of August 18-22, 2025, outperforming the Shanghai Composite Index by 2.20 percentage points [12][20] - The internet e-commerce sector showed the highest growth, with a weekly increase of 7.71% [13][17] - Year-to-date, the jewelry sector has led with a 33.74% increase [13][17] Retail Insights: Mid-Year Reports - Gold jewelry companies like Laopuhuang and Chaohongji reported significant revenue growth, with Laopuhuang achieving a revenue of 12.354 billion yuan (+251.0%) and a net profit of 2.268 billion yuan (+285.8%) [23][35] - Beauty care brands such as Shanghai Jahwa and Runben also showed positive performance, with Shanghai Jahwa reporting a net profit of 266 million yuan (+11.7%) [27][38] Focus on High-Quality Companies - Investment focus includes: - Gold jewelry brands with differentiated product offerings, recommending Laopuhuang and Chaohongji [30][32] - Offline retail companies adapting to trends, recommending Yonghui Supermarket and Aiyingshi [30][32] - High-quality domestic beauty brands, recommending Maogeping and Pola [30][32] - Medical beauty product manufacturers, recommending Aimeike and Kedi-B [30][32] Company-Specific Highlights - Laopuhuang: Achieved a revenue of 12.354 billion yuan (+250.9%) and a net profit of 2.268 billion yuan (+285.8%) in H1 2025, with strong brand expansion and channel upgrades [35][36] - Runben: Reported a revenue of 895 million yuan (+20.3%) and a net profit of 188 million yuan (+4.2%) in H1 2025, focusing on expanding its product matrix [38][40] - Aiyingshi: Achieved a revenue of 1.835 billion yuan (+8.3%) and a net profit of 46.74 million yuan (+10.2%) in H1 2025, with steady store expansion [42]